Matthew McClure has been appointed executive vice president and chief medical officer of South San Francisco-based Aligos Therapeutics. He was most recently the chief medical officer of Second Genome. McClure’s experience also includes time at InterMune, which was acquired by Roche in 2014. Preclinical-stage Aligos is developing treatments for liver diseases and viral infections.
From Our Partners · Special Report
Advice for funding and future transformational opportunities
From Our Editors · Special Report
Key indicators & expert insight from industry leaders
Xconomy
Xconomy Insight · Special Report
Insights, wisdom, and inspiration on what it takes
